Cart
sales@molnova.com
HNPMI
CAS No. 1980848-48-3
HNPMI( —— )
Catalog No. M37340 CAS No. 1980848-48-3
HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 53 | Get Quote |
|
| 10MG | 88 | Get Quote |
|
| 25MG | 174 | Get Quote |
|
| 50MG | 273 | Get Quote |
|
| 100MG | 439 | Get Quote |
|
| 500MG | 954 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHNPMI
-
NoteResearch use only, not for human use.
-
Brief DescriptionHNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
-
DescriptionHNPMI is an inhibitor of EGFR and has cytotoxic effects on tumor cells. HNPMI can downregulate the protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. HNPMI also regulates BCL-2/BAX and p53 in CRC cell lines to inhibit tumorigenesis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1980848-48-3
-
Formula Weight360.41
-
Molecular FormulaC22H20N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=[N+]([O-])C1=CC=C(C(C(N2C3=C(CC2)C=CC=C3)C4=CC=C(C)C=C4)=C1)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kandhavelu J, et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer. Br J Pharmacol. 2024 Jan;181(1):107-124.?
molnova catalog
related products
-
SMIP004
SMIP004 is an SKP2 E3 ligase inhibitor. SMIP004 is a cancer cell-selective apoptosis inducer of human prostate cancer cells.
-
M3541
M3541 is a selectively potent and orally active ATM inhibitor with potential antitumor activity.M-3541 inhibits ATM kinase activity and ATM-mediated signaling by binding to ATM.
-
RAPTA-C
RAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.
